LXX Lexaria Corp.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the  @  (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,

please visit:  

The prestigious “New England Journal of Medicine” recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight.

But there may be an even better avenue to increased effectiveness and better outcomes. Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better.

About Lexaria Bioscience Corp.

Lexaria’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide.

For more information, visit the company’s website at .

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at 

About NetworkNewsWire

 (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the  @  that delivers: (1) access to a vast network of wire solutions via  to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and ; (3)  to ensure maximum impact; (4)  via IBN to millions of social media followers; and (5) a full array of tailored . With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit 

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished:

NetworkNewsWire

New York, NY



212.418.1217 Office

NetworkNewsWire is powered by 



EN
31/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexaria Corp.

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery Syst...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:  With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of ...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs,” please visi...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:    It shouldn’t be surprising that analysts at Markets and Research estimate the global diabetes drug market at $63.1 billion in 2021 on its way to $82.93 billion in 2027, while th...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-De...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the  @  (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,please visit:   The prest...

 PRESS RELEASE

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hy...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit:  In its 2021 industry report, estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion in 2025. All told, hypertension costs the country on average ann...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch